As the COVID-19 pandemic worsens in the U.S., there remains a critical lack of testing capability. We must test more people, or we cannot track and contain the virus. The Innovative Genomics Institute (IGI) is using our considerable scientific resources to expand testing capacity and turn-around time. The IGI is a Bay Area research partnership founded by Jennifer Doudna, co-developer of CRISPR, to use science for the public good.
We are now working around the clock to set up a clinical COVID-19 testing lab at the IGI that will analyze patient samples collected by clinical partners. An effort of this nature is extremely challenging and requires staff at multiple institutions, new equipment, new reagents and extensive administrative support.
Looking ahead, we are developing point-of-care diagnostic tests and launching strategic research projects to understand the virus and combat it with new therapeutics.
Contributions of any size get us closer to accomplishing our important goals.
Thank you for your support!
For more information, contact:
IGI COVID-19 Rapid Research Response Team